サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1708019

個別化医療バイオマーカーの世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）

Personalized Medicine Biomarker Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 180 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
個別化医療バイオマーカーの世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）
出版日: 2025年04月15日
発行: Persistence Market Research
ページ情報: 英文 180 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の個別化医療バイオマーカーの市場規模は、2025年に211億4,880万米ドルになるとみられ、2025年～2032年の予測期間に14.2%のCAGRで拡大し、2032年には535億7,340万米ドルに達すると予測されています。

個別化医療バイオマーカー市場は、遺伝子、プロテオミクス、代謝プロファイルに基づいて個々の患者に合わせた治療を支援する生物学的マーカーの開発と利用に焦点を当てています。これらのバイオマーカーは、疾患の診断、治療法の選択、薬剤開発、治療モニタリングにおいて重要な役割を果たします。プレシジョン・ヘルスケアがますます重視されるようになるにつれ、臨床的意思決定におけるバイオマーカーの統合が大きく進展しています。ゲノム技術の革新、標的治療に対する需要の高まり、慢性疾患の負担増は、市場成長を加速する主要因です。

世界の個別化医療バイオマーカー市場の成長は、いくつかの有力な要因によって牽引されています。バイオ医薬品の研究開発への多額の投資に支えられたゲノムおよびプロテオミクス研究の急速な拡大が、新規バイオマーカーの発見を可能にしています。がん、糖尿病、神経疾患などの複雑な疾患の有病率の増加は、個別化治療戦略の採用を促し、バイオマーカーの需要をさらに押し上げています。さらに、次世代シーケンサー（NGS）やバイオインフォマティクスツールの進歩により、バイオマーカーに基づく診断の精度と効率が向上しています。精密医療プログラムを支援する政府のイニシアチブは、病気の早期発見に対する一般市民の意識の高まりと相まって、市場の拡大をさらに後押ししています。

関心と可能性の高まりにもかかわらず、個別化医療バイオマーカー市場は一定の抑制要因に直面しています。バイオマーカーの発見、検証、規制当局の承認に関連する高コストが、特に中低所得地域における普及の妨げとなる可能性があります。バイオマーカーに基づく検査を日常的な臨床ワークフローに組み込むことの複雑さに加え、データのプライバシーや遺伝子検査にまつわる倫理的懸念に関連する問題も、さらなるハードルとなっています。さらに、標準化されたプロトコルがないことや、地域によって償還政策に一貫性がないことも、市場浸透を制限する要因となっています。

個別化医療バイオマーカー市場には、長期的な成長を約束する機会が数多く存在します。バイオマーカー探索とデータ解析における人工知能と機械学習の利用が増加しており、開発パイプラインの合理化と診断精度の向上が進んでいます。新興国におけるヘルスケアインフラの拡大と個別化医療への投資の拡大は、市場関係者に大きな可能性をもたらしています。さらに、特にがん領域におけるコンパニオン診断の動向の高まりは、診断薬企業と製薬企業との新たな協力の道を開くものです。戦略的パートナーシップ、臨床試験の革新、マルチオミクスアプローチへの投資は、市場の差別化と拡大のさらなる機会を提供します。

当レポートでは、世界の個別化医療バイオマーカー市場について調査し、バイオマーカータイプ別、用途別、適応疾患別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の範囲と定義
  • 市場力学
  • マクロ経済要因
  • COVID-19の影響分析
  • 予測要因- 関連性と影響

第3章 付加価値のある洞察

第4章 世界の個別化医療バイオマーカー市場の見通し

  • 主なハイライト
  • 市場規模分析と予測
    • 過去の市場規模分析、2019年～2024年
    • 現在の市場規模分析と予測、2025年～2032年
  • 世界の個別化医療バイオマーカー市場の見通し：バイオマーカータイプ別
    • イントロダクション/主な調査結果
    • 過去の市場規模分析、バイオマーカータイプ別、2019年～2024年
    • 現在の市場規模分析と予測、バイオマーカータイプ別、2025年～2032年
    • 市場の魅力分析：、バイオマーカータイプ別
  • 世界の個別化医療バイオマーカー市場の見通し：用途別
    • イントロダクション/主な調査結果
    • 過去の市場規模分析、用途別、2019年～2024年
    • 現在の市場規模分析と予測、用途別、2025年～2032年
    • 市場の魅力分析：用途別
  • 世界の個別化医療バイオマーカー市場の見通し：適応疾患別
    • イントロダクション/主な調査結果
    • 過去の市場規模分析、適応疾患別、2019年～2024年
    • 現在の市場規模分析と予測、適応疾患別、2025年～2032年
    • 市場の魅力分析：適応疾患別
  • 世界の個別化医療バイオマーカー市場の見通し：エンドユーザー別
    • イントロダクション/主な調査結果
    • 過去の市場規模分析、エンドユーザー別、2019年～2024年
    • 現在の市場規模分析と予測、エンドユーザー別、2025年～2032年
    • 市場の魅力分析：エンドユーザー別

第5章 世界の個別化医療バイオマーカー市場の見通し：地域別

  • 主なハイライト
  • 過去の市場規模分析、地域別、2019年～2024年
  • 現在の市場規模分析と予測、地域別、2025年～2032年
    • 北米
    • 欧州
    • 東アジア
    • 南アジアとオセアニア
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力分析：地域別

第6章 北米の個別化医療バイオマーカー市場の見通し

第7章 欧州の個別化医療バイオマーカー市場の見通し

第8章 東アジアの個別化医療バイオマーカー市場の見通し

第9章 南アジアおよびオセアニアの個別化医療バイオマーカー市場の見通し

第10章 ラテンアメリカの個別化医療バイオマーカー市場の見通し

第11章 中東・アフリカの個別化医療バイオマーカー市場の見通し

第12章 競合情勢

  • 市場シェア分析、2025年
  • 市場構造
  • 企業プロファイル（詳細- 概要、財務、戦略、最近の動向）
    • Abbott Laboratories
    • Bio-Rad Laboratories
    • Danaher
    • EKF Diagnostics Holdings
    • F. Hoffmann-La Roche
    • Illumina
    • Merck
    • Myriad Genetics
    • QIAGEN
    • Signosis
    • Singulex
    • Thermo Fisher Scientific
    • Siemens Healthineers
    • PerkinElmer Inc.
    • Agilent Technologies, Inc.
    • Meso Scale Diagnostics
    • Enzo Biochem
    • Lifesign LLC
    • Guardant Health
    • Nexus-Dx
    • Proteome Sciences
    • Almac Diagnostics
    • Biocartis

第13章 付録

目次
Product Code: PMRREP35202

Persistence Market Research has recently released a comprehensive report on the global Personalized Medicine Biomarkers Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

  • Personalized Medicine Biomarkers Market Size (2025E): US$ 21,148.8 Mn
  • Projected Market Value (2032F): US$ 53,573.4 Mn
  • Global Market Growth Rate (CAGR 2025 to 2032): 14.2%

Personalized Medicine Biomarkers Market - Report Scope:

The personalized medicine biomarkers market focuses on the development and utilization of biological markers that aid in tailoring medical treatment to individual patients based on their genetic, proteomic, or metabolic profiles. These biomarkers play a critical role in disease diagnosis, treatment selection, drug development, and therapeutic monitoring. With increasing emphasis on precision healthcare, the integration of biomarkers in clinical decision-making has grown substantially. Innovations in genomic technologies, rising demand for targeted therapies, and the growing burden of chronic diseases are key factors accelerating market growth.

Market Growth Drivers:

The growth of the global personalized medicine biomarkers market is being driven by several influential factors. The rapid expansion of genomic and proteomic research, supported by significant investments in biopharmaceutical R&D, is enabling the discovery of novel biomarkers. Rising prevalence of complex diseases such as cancer, diabetes, and neurological disorders is prompting the adoption of personalized treatment strategies, further boosting demand for biomarkers. Additionally, advancements in next-generation sequencing (NGS) and bioinformatics tools are enhancing the accuracy and efficiency of biomarker-based diagnostics. Government initiatives supporting precision medicine programs, coupled with increasing public awareness about early disease detection, are further propelling market expansion.

Market Restraints:

Despite the growing interest and potential, the personalized medicine biomarkers market faces certain restraints. High costs associated with biomarker discovery, validation, and regulatory approvals can hinder widespread adoption, particularly in low- and middle-income regions. The complexity of integrating biomarker-based testing into routine clinical workflows, along with issues related to data privacy and ethical concerns around genetic testing, present additional hurdles. Furthermore, the lack of standardized protocols and inconsistent reimbursement policies across regions can limit market penetration.

Market Opportunities:

There are numerous opportunities within the personalized medicine biomarkers market that promise long-term growth. The increasing use of artificial intelligence and machine learning in biomarker discovery and data analysis is streamlining the development pipeline and improving diagnostic accuracy. Expanding healthcare infrastructure in emerging economies, combined with growing investments in personalized healthcare, offers significant potential for market players. Furthermore, the rising trend of companion diagnostics, particularly in oncology, opens new avenues for collaboration between diagnostic companies and pharmaceutical firms. Strategic partnerships, clinical trial innovations, and investment in multi-omics approaches present further opportunities for market differentiation and expansion.

Key Questions Answered in the Report:

  • What are the primary factors driving the global personalized medicine biomarkers market's growth?
  • Which biomarker types and applications are gaining the most traction across regions?
  • How are technological advancements shaping the future of biomarker-driven diagnostics and treatment?
  • Who are the key players in the personalized medicine biomarkers market, and what are their growth strategies?
  • What are the major trends, challenges, and opportunities shaping the global market outlook?

Competitive Intelligence and Business Strategy:

Leading companies in the personalized medicine biomarkers market, including Abbott Laboratories, F. Hoffmann-La Roche, Illumina, and QIAGEN, are actively investing in R&D to advance biomarker discovery and develop integrated diagnostic platforms. These players are forming strategic alliances with pharmaceutical companies to co-develop companion diagnostics and personalized treatment solutions. Efforts are also being directed towards expanding biomarker portfolios across diverse disease areas such as oncology, cardiology, and neurology. Focus on clinical validation, regulatory compliance, and cost-effective assay development is enabling companies to strengthen their market positions and cater to evolving healthcare needs.

Companies Covered in This Report:

  • Abbott Laboratories
  • Bio-Rad Laboratories
  • Danaher
  • EKF Diagnostics Holdings
  • F. Hoffmann-La Roche
  • Illumina
  • Merck
  • Myriad Genetics
  • QIAGEN
  • Signosis

Market Segmentation:

By Biomarker Type:

  • Genomic
  • Proteomics
  • Metabolic
  • Others

By Application:

  • Disease Diagnosis
  • Drug Discovery & Development
  • Therapeutic Monitoring
  • Treatment Selection
  • Others

By Disease Indication:

  • Oncology
  • Neurology
  • Diabetes
  • Autoimmune diseases
  • Cardiology
  • Others

By End-user:

  • Pharmaceutical & Biotechnology Companies
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Others

By Region:

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Personalized Medicine Biomarkers Market Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Regulatory Landscape
  • 3.2. Product Adoption Analysis
  • 3.3. Value Chain Analysis
  • 3.4. Key Deals and Mergers
  • 3.5. PESTLE Analysis
  • 3.6. Porter's Five Force Analysis

4. Global Personalized Medicine Biomarkers Market Outlook:

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Mn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
  • 4.3. Global Personalized Medicine Biomarkers Market Outlook: Biomarker Type
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Biomarker Type, 2019-2024
    • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker Type, 2025-2032
      • 4.3.3.1. Genomic
      • 4.3.3.2. Proteomics
      • 4.3.3.3. Metabolic
      • 4.3.3.4. Others
    • 4.3.4. Market Attractiveness Analysis: Biomarker Type
  • 4.4. Global Personalized Medicine Biomarkers Market Outlook: Application
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Mn) Analysis, By Application, 2019-2024
    • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
      • 4.4.3.1. Disease Diagnosis
      • 4.4.3.2. Drug Discovery & Development
      • 4.4.3.3. Therapeutic Monitoring
      • 4.4.3.4. Treatment Selection
      • 4.4.3.5. Others
    • 4.4.4. Market Attractiveness Analysis: Application
  • 4.5. Global Personalized Medicine Biomarkers Market Outlook: Disease Indication
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Mn) Analysis, By Disease Indication, 2019-2024
    • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
      • 4.5.3.1. Oncology
      • 4.5.3.2. Neurology
      • 4.5.3.3. Diabetes
      • 4.5.3.4. Autoimmune diseases
      • 4.5.3.5. Cardiology
      • 4.5.3.6. Others
    • 4.5.4. Market Attractiveness Analysis: Disease Indication
  • 4.6. Global Personalized Medicine Biomarkers Market Outlook: End User
    • 4.6.1. Introduction / Key Findings
    • 4.6.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2024
    • 4.6.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
      • 4.6.3.1. Pharmaceutical & Biotechnology Companies
      • 4.6.3.2. Hospitals & Clinics
      • 4.6.3.3. Diagnostic Laboratories
      • 4.6.3.4. Others
    • 4.6.4. Market Attractiveness Analysis: End User

5. Global Personalized Medicine Biomarkers Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Personalized Medicine Biomarkers Market Outlook:

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Biomarker Type
    • 6.2.3. By Application
    • 6.2.4. By Disease Indication
    • 6.2.5. By End User
  • 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker Type, 2025-2032
    • 6.4.1. Genomic
    • 6.4.2. Proteomics
    • 6.4.3. Metabolic
    • 6.4.4. Others
  • 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 6.5.1. Disease Diagnosis
    • 6.5.2. Drug Discovery & Development
    • 6.5.3. Therapeutic Monitoring
    • 6.5.4. Treatment Selection
    • 6.5.5. Others
  • 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
    • 6.6.1. Oncology
    • 6.6.2. Neurology
    • 6.6.3. Diabetes
    • 6.6.4. Autoimmune diseases
    • 6.6.5. Cardiology
    • 6.6.6. Others
  • 6.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 6.7.1. Pharmaceutical & Biotechnology Companies
    • 6.7.2. Hospitals & Clinics
    • 6.7.3. Diagnostic Laboratories
    • 6.7.4. Others
  • 6.8. Market Attractiveness Analysis

7. Europe Personalized Medicine Biomarkers Market Outlook:

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Biomarker Type
    • 7.2.3. By Application
    • 7.2.4. By Disease Indication
    • 7.2.5. By End User
  • 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker Type, 2025-2032
    • 7.4.1. Genomic
    • 7.4.2. Proteomics
    • 7.4.3. Metabolic
    • 7.4.4. Others
  • 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 7.5.1. Disease Diagnosis
    • 7.5.2. Drug Discovery & Development
    • 7.5.3. Therapeutic Monitoring
    • 7.5.4. Treatment Selection
    • 7.5.5. Others
  • 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
    • 7.6.1. Oncology
    • 7.6.2. Neurology
    • 7.6.3. Diabetes
    • 7.6.4. Autoimmune diseases
    • 7.6.5. Cardiology
    • 7.6.6. Others
  • 7.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 7.7.1. Pharmaceutical & Biotechnology Companies
    • 7.7.2. Hospitals & Clinics
    • 7.7.3. Diagnostic Laboratories
    • 7.7.4. Others
  • 7.8. Market Attractiveness Analysis

8. East Asia Personalized Medicine Biomarkers Market Outlook:

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Biomarker Type
    • 8.2.3. By Application
    • 8.2.4. By Disease Indication
    • 8.2.5. By End User
  • 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker Type, 2025-2032
    • 8.4.1. Genomic
    • 8.4.2. Proteomics
    • 8.4.3. Metabolic
    • 8.4.4. Others
  • 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 8.5.1. Disease Diagnosis
    • 8.5.2. Drug Discovery & Development
    • 8.5.3. Therapeutic Monitoring
    • 8.5.4. Treatment Selection
    • 8.5.5. Others
  • 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
    • 8.6.1. Oncology
    • 8.6.2. Neurology
    • 8.6.3. Diabetes
    • 8.6.4. Autoimmune diseases
    • 8.6.5. Cardiology
    • 8.6.6. Others
  • 8.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 8.7.1. Pharmaceutical & Biotechnology Companies
    • 8.7.2. Hospitals & Clinics
    • 8.7.3. Diagnostic Laboratories
    • 8.7.4. Others
  • 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Personalized Medicine Biomarkers Market Outlook:

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Biomarker Type
    • 9.2.3. By Application
    • 9.2.4. By Disease Indication
    • 9.2.5. By End User
  • 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker Type, 2025-2032
    • 9.4.1. Genomic
    • 9.4.2. Proteomics
    • 9.4.3. Metabolic
    • 9.4.4. Others
  • 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 9.5.1. Disease Diagnosis
    • 9.5.2. Drug Discovery & Development
    • 9.5.3. Therapeutic Monitoring
    • 9.5.4. Treatment Selection
    • 9.5.5. Others
  • 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
    • 9.6.1. Oncology
    • 9.6.2. Neurology
    • 9.6.3. Diabetes
    • 9.6.4. Autoimmune diseases
    • 9.6.5. Cardiology
    • 9.6.6. Others
  • 9.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 9.7.1. Pharmaceutical & Biotechnology Companies
    • 9.7.2. Hospitals & Clinics
    • 9.7.3. Diagnostic Laboratories
    • 9.7.4. Others
  • 9.8. Market Attractiveness Analysis

10. Latin America Personalized Medicine Biomarkers Market Outlook:

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Biomarker Type
    • 10.2.3. By Application
    • 10.2.4. By Disease Indication
    • 10.2.5. By End User
  • 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker Type, 2025-2032
    • 10.4.1. Genomic
    • 10.4.2. Proteomics
    • 10.4.3. Metabolic
    • 10.4.4. Others
  • 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 10.5.1. Disease Diagnosis
    • 10.5.2. Drug Discovery & Development
    • 10.5.3. Therapeutic Monitoring
    • 10.5.4. Treatment Selection
    • 10.5.5. Others
  • 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
    • 10.6.1. Oncology
    • 10.6.2. Neurology
    • 10.6.3. Diabetes
    • 10.6.4. Autoimmune diseases
    • 10.6.5. Cardiology
    • 10.6.6. Others
  • 10.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 10.7.1. Pharmaceutical & Biotechnology Companies
    • 10.7.2. Hospitals & Clinics
    • 10.7.3. Diagnostic Laboratories
    • 10.7.4. Others
  • 10.8. Market Attractiveness Analysis

11. Middle East & Africa Personalized Medicine Biomarkers Market Outlook:

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Biomarker Type
    • 11.2.3. By Application
    • 11.2.4. By Disease Indication
    • 11.2.5. By End User
  • 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker Type, 2025-2032
    • 11.4.1. Genomic
    • 11.4.2. Proteomics
    • 11.4.3. Metabolic
    • 11.4.4. Others
  • 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 11.5.1. Disease Diagnosis
    • 11.5.2. Drug Discovery & Development
    • 11.5.3. Therapeutic Monitoring
    • 11.5.4. Treatment Selection
    • 11.5.5. Others
  • 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
    • 11.6.1. Oncology
    • 11.6.2. Neurology
    • 11.6.3. Diabetes
    • 11.6.4. Autoimmune diseases
    • 11.6.5. Cardiology
    • 11.6.6. Others
  • 11.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 11.7.1. Pharmaceutical & Biotechnology Companies
    • 11.7.2. Hospitals & Clinics
    • 11.7.3. Diagnostic Laboratories
    • 11.7.4. Others
  • 11.8. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Abbott Laboratories
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Bio-Rad Laboratories
    • 12.3.3. Danaher
    • 12.3.4. EKF Diagnostics Holdings
    • 12.3.5. F. Hoffmann-La Roche
    • 12.3.6. Illumina
    • 12.3.7. Merck
    • 12.3.8. Myriad Genetics
    • 12.3.9. QIAGEN
    • 12.3.10. Signosis
    • 12.3.11. Singulex
    • 12.3.12. Thermo Fisher Scientific
    • 12.3.13. Siemens Healthineers
    • 12.3.14. PerkinElmer Inc.
    • 12.3.15. Agilent Technologies, Inc.
    • 12.3.16. Meso Scale Diagnostics
    • 12.3.17. Enzo Biochem
    • 12.3.18. Lifesign LLC
    • 12.3.19. Guardant Health
    • 12.3.20. Nexus-Dx
    • 12.3.21. Proteome Sciences
    • 12.3.22. Almac Diagnostics
    • 12.3.23. Biocartis

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations